The market's opinion of the business has improved over the past five years, reflecting a track record of earnings growth. The company's strategy appears to be drawing new investors, with an average annual return of 10% over five years.
Gainers: •$Checkmate Pharmaceuticals (CMPI.US)$+331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash) •$アクサム・セラピューティクス (AXSM.US)$+27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder) •$スーパー・マイクロ・コンピューター (SMCI.US)$+14.3% (earnings report) •$プラグ・パワー (PLUG.US)$+9.24% (t...
エフエヌビーに関するコメント
In reaction to earnings/guidance:
• $スーパー・マイクロ・コンピューター (SMCI.US)$ +18%, $ノキア (NOK.US)$ +7.7%, $ダナハー (DHR.US)$ +6.3%, $アールエルアイ (RLI.US)$ +5%, $シーエスエックス (CSX.US)$ +4.3%, $ラスベガス・サンズ (LVS.US)$ +4.2%, $アルコア (AA.US)$ +3.4%(also authorizes new $500 mln share repurchase program)
• $スチール・ダイナミクス (STLD.US)$ +2.8%, $ハーク・ホールディングス (HRI.US)$ +2.6%, $テスラ (TSLA.US)$ +2.5%, $フィリップ・モリス・インターナショナル (PM.US)$ +2.5%, $エフエヌビー (FNB.US)$ ...
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $アクサム・セラピューティクス (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $スーパー・マイクロ・コンピューター (SMCI.US)$ +14.3% (earnings report)
• $プラグ・パワー (PLUG.US)$ +9.24% (t...
まだコメントはありません